Use of celastrol or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating ketoacidosis or symptoms resulting therefrom
By using triptolide to prepare the drug, the risk of ketoacidosis caused by SGLT2i was resolved, β-hydroxybutyrate levels were significantly reduced, and HMGCS2 expression was decreased, providing an effective treatment and prevention strategy for ketoacidosis.
Patent Information
- Application Number
- CN202610362476.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-24
- Publication Date
- 2026-08-04
- Estimated Expiration
- 2046-03-24
AI Technical Summary
In the prior art, sodium-glucose cotransporter 2 inhibitors (SGLT2i) increase the risk of diabetic ketoacidosis, and the clinical manifestations of ketoacidosis are atypical, which can easily delay diagnosis and treatment.
Tripterygium wilfordii or its pharmaceutically acceptable salts are used to prepare drugs for the treatment or prevention of ketoacidosis and its symptoms through various routes of administration, including improving, reducing, alleviating, curing, delaying and preventing recurrence.
Tripterygium wilfordii significantly reduces β-hydroxybutyrate levels associated with ketoacidosis, decreases disease severity, and reduces HMGCS2 expression, providing an effective treatment and prevention strategy.
Smart Images

Figure CN121971452B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to the use of triptolide or its pharmaceutically acceptable salts in the preparation of medicaments for treating ketoacidosis or its symptoms. Background Technology
[0002] Ketogenesis primarily occurs in the mitochondrial matrix of hepatocytes, through the breakdown of free fatty acids to produce soluble ketone bodies—acetone, acetoacetate (AcAc), and β-hydroxybutyrate (β-OHB). These ketone bodies serve as energy substrates in extrahepatic tissues. Under the catalysis of acyl-CoA synthase, free fatty acids are activated into acyl-CoA, which then crosses the mitochondrial membrane and undergoes β-oxidation. The rate-limiting enzyme in ketogenesis, 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), catalyzes the condensation of acetoacetyl-CoA (AcAc-CoA) and acetyl-CoA to form hydroxymethylglutaryl-CoA. This intermediate is then cleaved by hydroxymethylglutaryl-coenzyme A lyase (HMGCL), releasing acetyl-CoA and acetoacetic acid. Acetoacetic acid can be further reduced to β-hydroxybutyrate or spontaneously decarboxylated to acetone. Ketogenesis is physiologically enhanced when carbohydrate reserves are depleted or fatty acid supply increases. However, excessive ketone body production can lead to ketoacidosis, characterized by the accumulation of acidic ketone bodies. Diabetic ketoacidosis (DKA) is an acute and life-threatening complication of diabetes, characterized by hyperglycemia, metabolic acidosis, and ketosis. Euglenic diabetic ketoacidosis (EDKA) presents with the same metabolic acidosis and ketosis as DKA, but blood glucose levels are not significantly elevated (blood glucose <200 mg / dL). Due to its atypical clinical presentation, EDKA is often undiagnosed or diagnosed late, thus delaying treatment. Known triggers for EDKA include reduced calorie intake, excessive alcohol consumption, chronic liver disease, glycogen storage disease, and recent use of insulin or sodium-glucose cotransporter-2 inhibitors (SGLT2i).
[0003] SGLT2 inhibitors are a class of hypoglycemic agents used to treat type 2 diabetes (T2D). Their mechanism of action is to inhibit the reabsorption of glucose by the kidneys. However, SGLT2 inhibitors increase the risk of diabetic ketoacidosis (including emergency diabetic ketoacidosis). These risks highlight the clinical need for effective prevention and treatment strategies to manage SGLT2 inhibitor-induced diabetic ketoacidosis. Summary of the Invention
[0004] The purpose of this invention is to provide the use of triptolide or its pharmaceutically acceptable salt in the preparation of a medicament for treating ketoacidosis or its symptoms, in order to solve the problems existing in the prior art.
[0005] To achieve the above objectives, the present invention provides the following solution: This invention provides the use of triptolide or its pharmaceutically acceptable salt in the preparation of a medicament for treating ketoacidosis or its symptoms.
[0006] Tripterygium wilfordii, also known as Celastrol, or (2R,4aS,6aS,6aR,14aS,14bR)-10-Hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid.
[0007] In this invention, the treatment should be given its broadest understanding, including but not limited to improving, reducing, alleviating, curing, delaying, preventing recurrence, and reducing morbidity.
[0008] In this invention, the ketoacidosis or its symptoms include worsening of diabetes symptoms caused by the disease, gastrointestinal symptoms, respiratory changes, dehydration and shock symptoms, and altered mental status.
[0009] Optionally, the ketoacidosis includes one or more of the following: ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors, alcoholic ketoacidosis, and type 1 diabetic ketoacidosis.
[0010] Optionally, the pharmaceutical salt includes one or more of the following: hydrochloride, sulfate, phosphate, nitrate, lactate, hydrobromide, hydroiodide, maleate, fumarate, citrate, formate, benzoate, acetate, trifluoroacetate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, succinate, salicylate, and ascorbate.
[0011] Optionally, the pharmaceutical salt includes one or more of the following: hydrochloride, sulfate, phosphate, lactate, fumarate, and citrate.
[0012] Optionally, the medicinal salt includes hydrochloride.
[0013] Optionally, the drug may also include pharmaceutically acceptable excipients.
[0014] This invention provides the use of triptolide or its pharmaceutically acceptable salt in the preparation of a medicament for the prevention of ketoacidosis or its symptoms.
[0015] In this invention, the term "prevention" should be given its broadest understanding, including but not limited to improving, reducing, alleviating, curing, delaying, preventing recurrence, and reducing morbidity.
[0016] Optionally, the ketoacidosis includes one or more of the following: ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors, alcoholic ketoacidosis, and type 1 diabetic ketoacidosis.
[0017] Optionally, the pharmaceutical salt includes one or more of the following: hydrochloride, sulfate, phosphate, nitrate, lactate, hydrobromide, hydroiodide, maleate, fumarate, citrate, formate, benzoate, acetate, trifluoroacetate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, succinate, salicylate, and ascorbate.
[0018] Optionally, the pharmaceutical salt includes one or more of the following: hydrochloride, sulfate, phosphate, lactate, fumarate, and citrate.
[0019] Optionally, the medicinal salt includes hydrochloride.
[0020] Optionally, the medicament may also include pharmaceutically acceptable excipients. The medicament of the present invention may be administered to an individual in need of the medicament via any of a number of routes, including but not limited to: local, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, percutaneous, subcutaneous, intraperitoneal, intranasal, intestinal, local, sublingual, or rectal routes.
[0021] Taking oral dosage forms as an example, these can be solid dosage forms such as tablets, capsules, powders, granules, or liquid dosage forms such as solutions, suspensions, etc. Dosage forms suitable for oral administration may contain pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers suitable for solid dosage forms (such as tablets or capsules) can be: for example, binders (such as gum arabic, gelatin, dextrin, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidone), diluents (such as lactose, sucrose, mannitol, corn starch, potato starch, calcium phosphate, calcium citrate, crystalline cellulose), lubricants (such as magnesium stearate, calcium stearate, stearic acid, talc, anhydrous silica gel), disintegrants (such as corn starch, potato starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, alginic acid), solid dispersants (such as polyethylene glycol-4000, polyethylene glycol-6000, polyvinylpyrrolidone (PVP), and poloxamerl88, urine...). Pharmaceutically acceptable carriers suitable for liquid formulations (such as solutions or suspensions) include: acids, organic acids (e.g., citric acid, succinic acid, cholic acid, deoxycholic acid, etc., as well as dextran, galactose, sucrose, pentaerythritol, and pentaerythritol acetate, etc.), and humectants (e.g., sodium lauryl sulfate). These carriers can include: aqueous solvents (e.g., water), suspending agents (e.g., gum arabic, gelatin, methylcellulose, sodium carboxymethyl cellulose, hydroxymethyl cellulose, aluminum stearate gel), surfactants (e.g., lecithin, sorbitan monooleate, glyceryl monostearate), and non-aqueous lysozymes (e.g., polyethylene glycol 400, glycerin, propylene glycol, vegetable oils). Furthermore, liquid formulations may contain preservatives (e.g., methylparaben, propylparaben), flavoring agents, and / or coloring agents.
[0022] According to some embodiments, a method for preventing or treating ketoacidosis or its symptoms is provided, the method comprising the step of administering a composition to a subject (including non-human animals and humans) comprising triptolide (or a pharmaceutically acceptable salt of triptolide) and a pharmaceutically acceptable carrier.
[0023] The dosage applied varies depending on factors including, but not limited to, the specific disease being treated, the subject's age, weight, health status, severity of symptoms, route of administration, frequency of treatment, and whether other medications are being used concurrently during treatment. The dosage of each active compound can be determined using conventional methods known to those skilled in the art.
[0024] The present invention discloses the following technical effects: This invention provides the use of triptolide or its pharmaceutically acceptable salts in the preparation of medicaments for treating ketoacidosis or its symptoms. Results from specific embodiments of this invention show that triptolide significantly reduces serum β-hydroxybutyrate (β-HBB) levels in starvation-induced mice; triptolide significantly reduces HMGCS2 expression in mouse livers; dapagliflozin significantly promotes β-HBB levels, while triptolide significantly reduces serum β-HBB levels in mice treated with dapagliflozin. Therefore, triptolide can be used to treat or improve ketoacidosis or its symptoms. This invention provides a new technical solution for the treatment and improvement of ketoacidosis or its symptoms. Attached Figure Description
[0025] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0026] Figure 1 The results of a survey on serum β-hydroxybutyrate levels in starvation model mice in the triptolide group and the control group; Figure 2 The results show the expression of HMGCS2 in the livers of the triptolide group and the control group; where A represents the results of Western blotting; and B represents the grayscale statistical results of the Western blotting results. Figure 3 The effect of triptolide on serum β-hydroxybutyrate levels in SGLT2i-induced T2D model mice. Detailed Implementation
[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0028] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.
[0029] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.
[0030] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.
[0031] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.
[0032] Tripterygium wilfordii, also known as Celastrol, or (2R,4aS,6aS,6aR,14aS,14bR)-10-Hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid.
[0033] In terms such as “serum β-hydroxybutyrate level”, “high” means outside the clinical reference range.
[0034] Example 1 1. Model Establishment Male C57BL / 6J mice aged 10-12 weeks were purchased from Huafukang Biotechnology Co., Ltd., and their housing and management were carried out in strict accordance with the standards for laboratory animals of the National Institutes of Health (NIH) and the Chinese Academy of Medical Sciences. The mice were housed in specific pathogen-free (SPF) cages with free access to food and water. The living conditions in the SPF-grade animal facility were as follows: diurnal rhythm (6:00 AM to 6:00 PM, with light), room temperature 22±2℃, and relative humidity 50±10%.
[0035] To establish a mouse model of type 2 diabetes (T2D), mice fed a high-fat diet (HFD; 60% of calories from fat, ResearchDiet) were injected with a low dose of streptozotocin (STZ). In short, 6-week-old male C57BL / 6 mice were fed HFD for 4 weeks, fasted for 12 hours, and then intraperitoneally injected with 40 mg / kg STZ (Abmole, Cat#M2082) for 5 consecutive days, followed by another 2 weeks of HFD feeding to obtain the T2D mouse model.
[0036] 2. Grouping Tripterygium wilfordii group (denoted as 1 or Cel): T2D mouse models were continuously injected intraperitoneally with triptolide at a dose of 1 mg / kg·d for 7 consecutive days, with a total of 5 mice treated.
[0037] Control group (denoted as 0 or Ctrl): T2D mouse models were intraperitoneally injected with an equal volume of phosphate-buffered saline (PBS) for 7 consecutive days, with a total of 5 mice treated.
[0038] Test Example 1: Tripterygium wilfordii reduced serum β-hydroxybutyrate levels in starved mice. Operating steps: 1. T2D mice in the triptolide group and the control group were injected for 6 consecutive days and then starved for a total of 48 hours. During the starvation period, they were also treated with triptolide and control PBS. 2. Determination of plasma β-hydroxybutyrate: After 48 hours of starvation, T2D mice were removed from their cages and gently placed on a wire mesh. The tail of each mouse was cut off by about 1-2 mm. The tail was gently squeezed to collect a drop of blood. The β-hydroxybutyrate level was measured using the FreeStyleOptium Neo system (Abbott). 3. Experiment completed. Results showed that the triptolide treatment group significantly reduced serum β-hydroxybutyrate levels in mice induced by starvation, such as... Figure 1 As shown.
[0039] Test Example 2: Tripterygium wilfordii significantly reduced the expression of HMGCS2 in mouse liver. Seven days after treatment with triptolide, the expression of HMGCS2 in the liver tissue of T2D mice was detected by Western blotting.
[0040] Operating steps: 1. Proteins were extracted from liver tissue samples of T2D mice in the triptolide group and control group using cell lysis buffers containing protease inhibitors (Western and IP cell lysis buffers, Beyotime Biotechnology). 2. Use the BCA Protein Detection Kit (LABLEAD, catalog number: B5000) to determine the protein concentration of each lysate to ensure equal loading volume; 3. Load equal amounts of protein onto a 10% SDS-polyacrylamide gel, and transfer the separated protein onto a PVDF membrane; 4. Perform Western blot analysis using specified specific antibodies, including anti-HMGCS2 antibody (Abclonal, catalog number: A14244) and anti-GAPDH antibody (CWBio, catalog number: CW0100M); quantify protein bands using ImageJ software. 5. Experiment complete.
[0041] The results showed that triptolide treatment significantly reduced the expression of HMGCS2 in the liver of mice. Figure 2 A, Western blotting results; Figure 2 (Statistical results of grayscale scanning of B in Western blotting results).
[0042] Test Example 3: Tripterygium wilfordii significantly reduced serum β-hydroxybutyrate levels in SGLT2i (dapagliflozin)-induced T2D model mice.
[0043] Operating steps: 1. Dapagliflozin treatment of T2D mice in the triptolide group and the control group: T2D mice in the triptolide group were treated for 7 days and then injected intraperitoneally with dapagliflozin (Dapa, 1 mg / kg; Abmole, Cat#M1937) after fasting for 4 hours. T2D mice in the control group were injected intraperitoneally with the control solvent (10% dimethyl sulfoxide-phosphate buffer) after fasting for 4 hours. All mice were then fasted for 8 hours and deprived of water. 2. Determination of plasma β-hydroxybutyrate: T2D mice were removed from their cages and gently placed on a wire mesh. Approximately 1-2 mm of the mouse's tail was cut off, and the tail was gently squeezed to collect a single drop of blood. Blood glucose levels were measured using a glucometer, followed by the determination of β-hydroxybutyrate levels using the FreeStyle Optium Neo system (Abbott). The procedure should be performed as gently as possible to avoid excessive stress on the mice. 3. Experiment complete.
[0044] The results showed that dapagliflozin significantly increased β-hydroxybutyrate levels, while triptolide significantly reduced dapagliflozin-induced serum β-hydroxybutyrate levels in mice. Figure 3 As shown.
[0045] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Claims
1. The use of triptolide or its pharmaceutically acceptable salts in the preparation of drugs for the treatment of ketoacidosis or its symptoms.
2. The application according to claim 1, characterized in that, The ketoacidosis includes one or more of the following: ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors, alcoholic ketoacidosis, and type 1 diabetic ketoacidosis.
3. The application according to claim 1, characterized in that, The pharmaceutical salts include one or more of the following: hydrochloride, sulfate, phosphate, nitrate, lactate, hydrobromide, hydroiodide, maleate, fumarate, citrate, formate, benzoate, acetate, trifluoroacetate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, succinate, salicylate, and ascorbate.
4. The application according to claim 3, characterized in that, The medicinal salts include one or more of the following: hydrochloride, sulfate, phosphate, lactate, fumarate, and citrate.
5. The application according to claim 4, characterized in that, The medicinal salts include hydrochloride salts.
6. The application according to claim 1, characterized in that, The drug also includes pharmaceutically acceptable excipients.
7. The use of triptolide or its medicinal salts in the preparation of drugs for the prevention of ketoacidosis or its symptoms.
8. The application according to claim 7, characterized in that, The ketoacidosis includes one or more of the following: ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors, alcoholic ketoacidosis, and type 1 diabetic ketoacidosis.
9. The application according to claim 7, characterized in that, The pharmaceutical salts include one or more of the following: hydrochloride, sulfate, phosphate, nitrate, lactate, hydrobromide, hydroiodide, maleate, fumarate, citrate, formate, benzoate, acetate, trifluoroacetate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, succinate, salicylate, and ascorbate.
10. The application according to claim 9, characterized in that, The medicinal salts include one or more of the following: hydrochloride, sulfate, phosphate, lactate, fumarate, and citrate.
